ArticleVeterinary research communications2023
T
Article in Veterinary research communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 4 citations in OpenAlex.
- Clinical-Diagnostic and Therapeutic Advances in Feline Hypertrophic Cardiomyopathy.Veterinary sciences · 2025Review
- Linking clinical and imaging diagnostic assessments of the feline hypertrophic cardiomyopathy phenotype.Frontiers in veterinary science · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertrophic cardiomyopathy (HCM) is the most common heart disease in feline species. ECG allows assessing parameters that can help in the diagnosis and risk stratification of conditions that occur secondary to this disease. This study aimed to evaluate electrocardiographic markers Tpte and Tpte/QT in leads I, II, III, aVR, aVL and aVF in control and HCM cats. Data were obtained from 63 domestic cats allocated in a Control (n = 40) and an HCM (n = 23) group. Tpte and Tpte/QT of all individuals were measured in all limb leads (I, II, III, aVR, aVL, aVF). We constructed ROC curves to evaluate the sensitivity and specificity of markers to identify HCM-affected cats. Logistic regression analysis was performed to assess the risks of cats having HCM based on Tpte indexes. Tpte in leads II (p < 0.01), aVR (p < 0.01), aVL (p < 0.01), and aVF (p < 0.01) had significantly higher results in the HCM group. Tpte/QT showed no statistical difference between groups in any of the derivations evaluated. A Tpte > 27.5ms in lead aVF showed an accuracy of 83.3% to identify individuals with HCM in our study. Univariable logistic regression reveals that cats with Tpte in aVR and aVF > 27.5ms and in aVL > 26.5ms had 1.28, 12 and 1.16 respectively, more chances of having HCM. The prolongation of Tpte may be a noninvasive electrocardiographic complementary tool to help differentiate patients with and without hypertrophic cardiomyopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.